News
VUV Analytics introduces HYDRA™: A breakthrough Vacuum Ultraviolet Detector for Liquid Chromatography
VUV Analytics, Inc., a global leader in vacuum ultraviolet (VUV) spectroscopy, is excited to introduce HYDRA, a breakthrough detector for Liquid Chromatography (LC). HYDRA makes advanced chemical analysis easier with universal detection, exceptional spectral selectivity, and seamless integration into lab workflows. “HYDRA is a major step forward for Liquid Chromatography
Read More
Novadip appoints Soumya Chandramouli as Chief Financial Officer
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare
Read More
San José City Council unanimously approves next phase of San José Airport Connector Project
San José Connection Partners, a consortium including Plenary Americas, Webcor/Obayashi, and HNTB, and Glydways has announced that the San José City Council voted unanimously to move the Diridon–Airport Connector into Phase 2a of project development. The decision marks a significant step toward achieving the City’s sustainable mobility goals, reflecting strong
Read More
NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.
Read More
Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of
Read MoreVentyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be
Read More
Phase Four Series C first closing
Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed
Read MoreNovadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion
Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced approval from the US Food and Drug Administration (FDA) for its allogenic bone grafting material NVDX3 to enter an investigational new drug study (IND). NVDX3 is an allogenic bone grafting material forming a new class of regenerative
Read More
Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI
Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost
Read MoreNovadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative
Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. Originating from Novadip’s 3M3 platform, NVDX3 is an allogeneic bone grafting material created from human
Read MorePhase Four announces monopropellant multi-mode propulsion systems
Phase Four, a leading provider of next-generation electric propulsion (EP) solutions for satellites, has announced the planned commercialization of their monopropellant multimode capability. Using their Maxwell Block III, Phase Four meets electric propulsion performance for a variety of mission profiles, using either ASCENT or hydrazine chemical propellants. Phase Four anticipates
Read MoreVentyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative
Read More